Inmune Bio and Quantum Computing Inc. will apply quantum optimization, AI and data analytics to clinical datasets spanning preclinical work through four trials of XPro, an investigational selective inhibitor of soluble tumor necrosis factor. The objective is to identify additional diseases and biomarkers driven by the same inflammatory biology the drug targets, beginning with rare diseases that permit smaller, faster trials. Outputs from the Dirac-3S machine will be benchmarked against conventional statistical and machine learning approaches.
Key Points
- Quantum optimization applied to XPro clinical datasets to find new indications
- XPro selectively inhibits soluble TNF while preserving other TNF functions
- Quantum outputs benchmarked against standard statistical and machine learning methods
Longevity Analysis
Soluble TNF sits at the intersection of immune signaling and neurodegeneration, and selectively blocking it without disabling the broader protective arm of tumor necrosis factor reflects a precision approach to chronic inflammation rather than blanket suppression. The computational layer addresses a separate problem: distinguishing which patients and which conditions are genuinely driven by this pathway, rather than inferring it from clinical presentation alone. Better biomarker stratification determines whether an anti-inflammatory intervention supports brain tissue maintenance or simply adds immunological risk.
Original published by LT Wire.